Benitec Biopharma Inc. - Common Stock, par value $0.0001 (BNTC)

CUSIP: 08205P209

Q2 2024 13F Holders as of 30 Jun 2024

Type / Class
Equity / Common Stock, par value $0.0001
Shares outstanding
35,393,481
Total 13F shares
5,729,459
Share change
+4,458,622
Total reported value
$39,940,820
Price per share
$6.99
Number of holders
18
Value change
+$31,087,038
Number of buys
14
Number of sells
3

Quarterly Holders Quick Answers

What is CUSIP 08205P209?
CUSIP 08205P209 identifies BNTC - Benitec Biopharma Inc. - Common Stock, par value $0.0001 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of BNTC - Benitec Biopharma Inc. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Steven Michael Oliveira
3/4/5
10%+ Owner
class O/S missing
1,000,000
$3,044,300 28 Apr 2021
FRANKLIN RESOURCES INC
13F
Company
1.7%
588,310
$3,012,147 31 Mar 2024
13F
JANUS HENDERSON GROUP PLC
13F
Company
0.69%
244,491
$1,266,463 31 Mar 2024
13F
SUVRETTA CAPITAL MANAGEMENT, LLC
13F
Company
0.58%
204,220
$1,072,155 31 Mar 2024
13F
ADAGE CAPITAL PARTNERS GP, L.L.C.
13F
Company
0.53%
189,188
$993,237 31 Mar 2024
13F
VANGUARD GROUP INC
13F
Company
0.05%
16,701
$87,680 31 Mar 2024
13F
MORGAN STANLEY
13F
Company
0.03%
11,800
$61,950 31 Mar 2024
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.03%
10,024
$51,322 31 Mar 2024
13F
GAMMA Investing LLC
13F
Company
0.01%
3,554
$18,659 31 Mar 2024
13F
Tower Research Capital LLC (TRC)
13F
Company
0%
1,745
$9,161 31 Mar 2024
13F
UBS Group AG
13F
Company
0%
512
$2,689 31 Mar 2024
13F
RHUMBLINE ADVISERS
13F
Company
0%
186
$952 31 Mar 2024
13F
GROUP ONE TRADING LLC
13F
Company
0%
89
$456 31 Mar 2024
13F
WELLS FARGO & COMPANY/MN
13F
Company
0%
17
$89 31 Mar 2024
13F

Institutional Holders of Benitec Biopharma Inc. - Common Stock, par value $0.0001 (BNTC) as of Q2 2024

As of 30 Jun 2024, Benitec Biopharma Inc. - Common Stock, par value $0.0001 (BNTC) was held by 18 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 5,729,459 shares. The largest 10 holders included SUVRETTA CAPITAL MANAGEMENT, LLC, JANUS HENDERSON GROUP PLC, Nantahala Capital Management, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., FRANKLIN RESOURCES INC, Schonfeld Strategic Advisors LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Simplify Asset Management Inc., and BlackRock Inc.. This page lists 18 institutional shareholders reporting positions in this security for the Q2 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders
13
Q2 2024 holders
18
Holder diff
5
Investor Q1 2024 Shares Q2 2024 Shares Share Diff Share Chg % Q1 2024 Value $ Q2 2024 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .